PsyMed Ventures | Activity | F4

PsyMed Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Essay

Published "The State of Frontier Neuroscience: This is the century of the brain" — a comprehensive thesis essay on why neuro is investable now, covering neurotech, programmable medicines, psychedelics, computational biology, brain foundation models, and human enhancement.

PsyMed Ventures

psymedventures.substack.comJUL 2, 2026

JUL 2, 2026

New Fund

Announced a $25M fund for early-stage mental health, psychedelics, neurotechnology, digital health, and precision psychology startups.

PsyMed Ventures $25M fund

PsyMed Ventures

news.crunchbase.com

Added recently

New Fund

Announced a $25M fund for early-stage psychedelics, mental health, neurotechnology, digital health, and precision psychology startups.

$25M PsyMed Ventures fund

PsyMed Ventures

psychiatrytech.com

Added recently

Essay

Published "Digital Addiction: The Investment Landscape + What Wins Now" — an investment thesis essay analyzing the digital addiction market, covering physical products, software-based well-being tools, and screen-free products for kids, with a focus on app blockers and hybrid consumer-institutional models.

PsyMed Ventures

psymedventures.substack.comAPR 7, 2026

APR 7, 2026

Milestone

Portfolio company Jimini Health raised $17M in seed funding to scale clinician-supervised AI for behavioral health.

Jimini Health

Jimini Health PsyMed Ventures

medcitynews.comMAR 31, 2026

mobihealthnews.com

MAR 31, 2026

Milestone

Portfolio company Aerska raised a $39M Series A financing led by EQT Dementia Fund and age1.

Aerska

AerskaPsyMed Ventures

finance.yahoo.comFEB 9, 2026

FEB 9, 2026

News

PsyMed Ventures and KdT Ventures hosted the 2nd annual Future Neuro Founders Program with 400+ founders from 190 universities, covering how to turn neuro ideas into companies.

Future Neuro Founders Program 2025

PsyMed Ventures

psymedventures.substack.comDEC 5, 2025

DEC 5, 2025

New Fund

Launched Fund II with a focus on frontier neuroscience, brain health, mental health, and human augmentation. Made three investments so far. Fund I performing in top decile for its vintage.

PsyMed Ventures Fund II

PsyMed Ventures

psymedventures.substack.comNOV 14, 2025

NOV 14, 2025

Milestone

Portfolio companies atai Life Sciences and Beckley Psytech completed their strategic combination to form AtaiBeckley.

ATAI Life Sciences

ATAI Life Sciences Beckley Psytech PsyMed Ventures

ir.ataibeckley.comNOV 5, 2025

nasdaq.com

NOV 5, 2025

Milestone

Delix Therapeutics reported positive Phase 1b results: lead non-hallucinogenic 5-MeO-DMT analog reduced depression symptoms by ~50% within a week, with benefits lasting weeks. FDA cleared Phase II design including at-home administration.

Delix Therapeutics

Delix Therapeutics PsyMed Ventures

psymedventures.substack.comNOV 2025

NOV 2025

Investment

Invested in Powerhouse Biology (precision peptide therapeutics for mitochondrial dysfunction) as part of Fund II portfolio.

Powerhouse Biology

Powerhouse Biology PsyMed Ventures

psymedventures.substack.comNOV 2025

NOV 2025

Exit

Portfolio company Gilgamesh Pharmaceuticals' bretisilocin program was acquired by AbbVie.

Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals PsyMed Ventures

prnewswire.comOCT 17, 2025

OCT 17, 2025

Investment

Participated in Aerska's $21M seed financing for RNAi medicines targeting neurological diseases.

Aerska

AerskaPsyMed Ventures

finsmes.comOCT 6, 2025

OCT 6, 2025

Exit

Portfolio company Gilgamesh Pharmaceuticals announced AbbVie's acquisition of its bretisilocin program.

Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals PsyMed Ventures

nasdaq.comAUG 25, 2025

AUG 25, 2025

Page 1 of 2